FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194345266> ?p ?o ?g. }

• W3194345266 endingPage "628" @default.
• W3194345266 startingPage "615" @default.
• W3194345266 abstract "<b><i>Introduction:</i></b> Immune checkpoint inhibitors (ICIs) are promising agents for the treatment of hepatocellular carcinoma (HCC). However, the establishment of noninvasive measure that could predict the response to ICIs is challenging. This study aimed to evaluate tumor responses to ICIs using the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), which was shown to reflect Wnt/β-catenin activating mutation. <b><i>Methods:</i></b> A total of 68 intrahepatic HCC nodules from 18 patients with unresectable HCC and Child-Pugh class A liver function who received anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy were enrolled in this study. All patients had viable intrahepatic lesions evaluable using the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI within the 6 months prior to the treatment. The relative enhancement ratio was calculated, and the time to nodular progression (TTnP) defined as 20% or more increase in each nodule was compared between higher or hypo-enhancement HCC nodules. Then, the progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) were compared between patients with and without HCC nodules with higher enhancement on hepatobiliary phase images. <b><i>Results:</i></b> The median PFS was 2.7 (95% confidence interval [CI]: 1.4–4.0) months in patients with HCC nodules with higher enhancement (<i>n</i> = 8) and 5.8 (95% CI: 0.0–18.9) months in patients with hypointense HCC nodules (<i>n</i> = 10) (<i>p</i> = 0.007). The median TTnP of HCC nodules with higher enhancement (<i>n</i> = 23) was 1.97 (95% CI: 1.86–2.07) months and that of hypointense HCC nodules (<i>n</i> = 45) was not reached (<i>p</i> = 0.003). The ORR was 12.5% (1/8) versus 30.0% (3/10); the disease control rate was 37.5% (3/8) versus 70.0% (7/10), respectively, in patients with or without higher enhancement intrahepatic HCC nodules. <b><i>Conclusion:</i></b> The TTnP on HCC nodules with higher enhancement and the median PFS in patients who carried higher enhancement intrahepatic HCC nodules were significantly shorter than those in hypointense HCC nodules with anti-PD-1/PD-L1 monotherapy. The intensity of the nodule on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI is a promising imaging biomarker for predicting unfavorable response with anti-PD-1/PD-L1 monotherapy in patients with HCC." @default.
• W3194345266 created "2021-08-30" @default.
• W3194345266 creator A5021075691 @default.
• W3194345266 creator A5030718094 @default.
• W3194345266 creator A5032900701 @default.
• W3194345266 creator A5036636103 @default.
• W3194345266 creator A5038487642 @default.
• W3194345266 creator A5043301078 @default.
• W3194345266 creator A5063658372 @default.
• W3194345266 creator A5067412557 @default.
• W3194345266 creator A5075875207 @default.
• W3194345266 creator A5076725199 @default.
• W3194345266 creator A5082908274 @default.
• W3194345266 creator A5084004721 @default.
• W3194345266 creator A5088207236 @default.
• W3194345266 date "2021-01-01" @default.
• W3194345266 modified "2023-10-16" @default.
• W3194345266 title "Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma" @default.
• W3194345266 cites W1586083286 @default.
• W3194345266 cites W1646740876 @default.
• W3194345266 cites W1938930503 @default.
• W3194345266 cites W1971837077 @default.
• W3194345266 cites W1972956861 @default.
• W3194345266 cites W1979185563 @default.
• W3194345266 cites W1989651038 @default.
• W3194345266 cites W1994193851 @default.
• W3194345266 cites W1996145004 @default.
• W3194345266 cites W2000928973 @default.
• W3194345266 cites W2004585555 @default.
• W3194345266 cites W2025948917 @default.
• W3194345266 cites W2026697625 @default.
• W3194345266 cites W2028591415 @default.
• W3194345266 cites W2064387090 @default.
• W3194345266 cites W2073421544 @default.
• W3194345266 cites W2076569927 @default.
• W3194345266 cites W2076668534 @default.
• W3194345266 cites W2084800358 @default.
• W3194345266 cites W2133557716 @default.
• W3194345266 cites W2139248078 @default.
• W3194345266 cites W2144688518 @default.
• W3194345266 cites W2163639981 @default.
• W3194345266 cites W2164241627 @default.
• W3194345266 cites W2277004004 @default.
• W3194345266 cites W2381763656 @default.
• W3194345266 cites W2560499218 @default.
• W3194345266 cites W2606367731 @default.
• W3194345266 cites W2612431515 @default.
• W3194345266 cites W2626033245 @default.
• W3194345266 cites W2787358630 @default.
• W3194345266 cites W2796067155 @default.
• W3194345266 cites W2805592007 @default.
• W3194345266 cites W2809889937 @default.
• W3194345266 cites W2883204623 @default.
• W3194345266 cites W2899174828 @default.
• W3194345266 cites W2908573150 @default.
• W3194345266 cites W2911120667 @default.
• W3194345266 cites W2917837889 @default.
• W3194345266 cites W2952311394 @default.
• W3194345266 cites W2959013777 @default.
• W3194345266 cites W2990602950 @default.
• W3194345266 cites W3012360622 @default.
• W3194345266 cites W3025022288 @default.
• W3194345266 cites W3041069444 @default.
• W3194345266 cites W3044291387 @default.
• W3194345266 cites W3080167134 @default.
• W3194345266 cites W3094021241 @default.
• W3194345266 cites W3172658199 @default.
• W3194345266 cites W2591655368 @default.
• W3194345266 doi "https://doi.org/10.1159/000518048" @default.
• W3194345266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34950184" @default.
• W3194345266 hasPublicationYear "2021" @default.
• W3194345266 type Work @default.
• W3194345266 sameAs 3194345266 @default.
• W3194345266 citedByCount "25" @default.
• W3194345266 countsByYear W31943452662021 @default.
• W3194345266 countsByYear W31943452662022 @default.
• W3194345266 countsByYear W31943452662023 @default.
• W3194345266 crossrefType "journal-article" @default.
• W3194345266 hasAuthorship W3194345266A5021075691 @default.
• W3194345266 hasAuthorship W3194345266A5030718094 @default.
• W3194345266 hasAuthorship W3194345266A5032900701 @default.
• W3194345266 hasAuthorship W3194345266A5036636103 @default.
• W3194345266 hasAuthorship W3194345266A5038487642 @default.
• W3194345266 hasAuthorship W3194345266A5043301078 @default.
• W3194345266 hasAuthorship W3194345266A5063658372 @default.
• W3194345266 hasAuthorship W3194345266A5067412557 @default.
• W3194345266 hasAuthorship W3194345266A5075875207 @default.
• W3194345266 hasAuthorship W3194345266A5076725199 @default.
• W3194345266 hasAuthorship W3194345266A5082908274 @default.
• W3194345266 hasAuthorship W3194345266A5084004721 @default.
• W3194345266 hasAuthorship W3194345266A5088207236 @default.
• W3194345266 hasBestOaLocation W31943452661 @default.
• W3194345266 hasConcept C126322002 @default.
• W3194345266 hasConcept C126838900 @default.
• W3194345266 hasConcept C143409427 @default.
• W3194345266 hasConcept C2776694085 @default.
• W3194345266 hasConcept C2778019345 @default.
• W3194345266 hasConcept C2779984678 @default.

• next